| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5657384 | Clinical Gastroenterology and Hepatology | 2017 | 10 Pages |
Abstract
Ustekinumab therapy was effective in patients with CD who had not responded to or were intolerant to treatment with a TNF antagonist. Maintenance trough concentrations of ustekinumab above 4.5 μg/mL at 26 weeks or later were associated with biomarker reduction and endoscopic response.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Robert Battat, Uri Kopylov, Talat Bessissow, Alain Bitton, Albert Cohen, Anjali Jain, Myriam Martel, Ernest Seidman, Waqqas Afif,